Lack of genotoxicity of tamoxifen in human endometrium.

The potential for the anti-breast cancer drug tamoxifen [(Z)-1-[4-[2-( dimethylamino)ethoxy]phenyl]-1,2-diphenyl-1-butene] to induce genotoxic damage (DNA adducts) in the human endometrium was investigated in vivo and in vitro. Endometria from hysterectomy patients who were not on tamoxifen were sectioned and maintained in short-term organ culture. The cultures were treated with either solvent vehicle (DMSO), tamoxifen, alpha-hydroxytamoxifen [(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,2-diphenyl-1-buten-3- ol; the major DNA-reactive metabolite in the rat], or benzo(a)pyrene. DNA was isolated and analyzed by 32P postlabeling. Chromatography on polyethyleneimine-cellulose TLC plates revealed DNA adducts in endometria treated with alpha-hydroxytamoxifen identical to those seen previously in the rat liver. However, no adducts were seen from treatment with tamoxifen itself. The viability of the enzyme-metabolizing systems of the endometrial samples was demonstrated by the detection of expected DNA adducts induced by benzo(a)pyrene. Examination by liquid chromatography-mass spectrometry of the explant culture media from endometria treated with tamoxifen revealed the presence of the alpha-hydroxy metabolite in a dose-dependent manner, although apparently at levels insufficient to produce detectable DNA adducts. Endometrial DNA obtained from 18 patients undergoing daily treatment with 10-40 mg tamoxifen for 3 months-9 years was also analyzed. No evidence for any DNA adducts induced by tamoxifen was found in any of the patients examined. These data suggest that the genotoxic events observed with tamoxifen in the rat may not apply to the human endometrium.

[1]  C M King,et al.  Tamoxifen and the induction of cancer. , 1995, Carcinogenesis.

[2]  D. Phillips,et al.  alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. , 1994, Cancer research.

[3]  S. Venitt,et al.  Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. , 1994, Carcinogenesis.

[4]  G. Williams,et al.  Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. , 1994, Cancer research.

[5]  Y. Dragan,et al.  Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. , 1994, Cancer research.

[6]  D. Phillips,et al.  Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. , 1994, Carcinogenesis.

[7]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[8]  D. N. Pathak,et al.  DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. , 1994, Carcinogenesis.

[9]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[10]  R. Gray.  Tamoxifen: how boldly to go where no women have gone before. , 1993, Journal of the National Cancer Institute.

[11]  T. Orton,et al.  Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. , 1993, Cancer research.

[12]  S. Ellard,et al.  Micronucleus assays using cytochalasin-blocked MCL-5 cells, a proprietary human cell line expressing five human cytochromes P-450 and microsomal epoxide hydrolase. , 1993, Mutagenesis.

[13]  S. Venitt,et al.  Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. , 1992, Carcinogenesis.

[14]  J. Liehr,et al.  Induction of covalent DNA adducts in rodents by tamoxifen. , 1992, Cancer research.

[15]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[16]  D. Kupfer,et al.  Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. , 1991, Cancer research.

[17]  F. Gonzalez,et al.  A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: application to mutagenicity testing. , 1991, Chemical research in toxicology.

[18]  D. Phillips,et al.  Formation of DNA adducts in human skin maintained in short‐term organ culture and treated with coal‐tar, creosote or bitumen , 1988, International journal of cancer.

[19]  G. Leclercq,et al.  Hydroxy derivatives of tamoxifen. , 1985, Journal of medicinal chemistry.

[20]  C. Redmond,et al.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.